Syntheses of biotinylated α-galactosylceramides and their effects on the immune system and CD1 molecules

Journal of Medicinal Chemistry

Volumn 42, Issue 10, 1999, Pages 1836-1841

  Sakai, Teruyuki ^a   Naidenko, Olga V ^b   Iijima, Hirosi ^a   Kronenberg, Mitchell ^b   Koezuka, Yasuhiko ^a  

^a KIRIN BREWERY CO LTD   (Japan)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 [N 12 [6 (BIOTINOYLAMINO)HEXANOYLAMINO]DODECANOYLAMINO] 1,3 OCTADECANEDIOL; 1 O (ALPHA GALACTOPYRANOSYL) 2 [N 12 [6 (BIOTINOYLAMINO)HEXANOYLAMINO]DODECANOYLAMINO] 1,3,4 OCTADECANETRIOL; 1 O (ALPHA GALACTOPYRANOSYL) 2 [N 12 [6 (BIOTINOYLAMINO)HEXANOYLAMINO]DODECANOYLAMINO]OCTADECANOL; 1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; AGL 592; AGL 593; AGL 594; ALPHA GALACTOSYLCERAMIDE DERIVATIVE; CD1 ANTIGEN; GALACTOSYLCERAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN PRESENTING CELL; ARTICLE; BIOTINYLATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; FEMALE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; SPLEEN CELL; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIGENS, CD1; BIOTINYLATION; CELL DIVISION; GALACTOSYLCERAMIDES; HUMANS; MICE; MICE, INBRED C57BL; PROTEIN BINDING; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP; SURFACE PLASMON RESONANCE;

EID: 0033587102     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990054n     Document Type: Article

References (25)

1. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Kobayashi, E.; Fukushima, H.; Koezuka, Y. Structure-activity relationship of α-galactosylceramides against B16-bearing mice. J. Med. Chem. 1995, 38, 2176-2187.
2. Nakagawa, R.; Motoki, K.; Ueno, H.; Iijima, R.; Nakamura, H.; Kobayashi, E.; Shimosaka, A.; Koezuka, Y. Treatment of hepatic metastasis of the Colon26 adenocarcinoma with α-galactosyl-ceramide, KRN7000. Cancer Res. 1998, 58, 1202-1207.
3. Kawano, T.; Cui, J.; Koezuka, Y.; Toura, I.; Kaneko, Y.; Motoki, K.; Ueno, H.; Nakagawa, R.; Sato, H.; Kondo, E.; Koseki, H.; Taniguchi, M. CD1d-restricted and TCR-mediated activation of Vα14 NKT cells by glycosylceramides. Science 1997, 278, 1626-1629.
4. Burdin, N.; Brossay, L.; Koezuka, Y.; Smiley, S. T.; Grusby, M. J.; Gui, M.; Taniguchi, M.; Hayakawa, K.; Kronenberg, M. Selective ability of mouse CD1 to present glycolipids: α-galactosylceramide specifically stimulates Vα14+ NKT lymphocytes. J. Immunol. 1998, 161, 3271-3281.
5. Broasay, L.; Chioda, M.; Burdin, N.; Koezuka, Y.; Casorati, G.; Dellabona, P.; Kronenberg, M. CD1d-mediated recognition of an α-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution. J. Exp. Med. 1998, 188, 1521-1528.
6. Spada, F.; Koezuka, Y.; Porcelli, S. A. CD1d-restricted recognition of synthetic glycolipid antigens by human NKT cells. J. Exp. Med. 1998, 188, 1529-1534.
7. Nieda, M.; Nicol, A.; Koezuka, Y.; Kikuchi, A.; Nakamura, H.; Takahashi, T.; Furukawa, H.; Yabe, T.; Ishikawa, Y.; Tadokoro, K.; Juji, T. Activation of human Vα24 NKT cells by an α-galactosylceramide in a CD1d-restricted and Vα24 TCR-mediated manner. Hum. Immunol. 1999, 60, 10-19.
8. Couedel, C.; Reyrat, M.-A.; Brossay, L.; Koezuka, Y.; Porcelli, S.; Davodeau, F.; Bonneville, M. Diverse CD1d-restricted reactivity patterns of human T cells bearing invariant AV24BV11 T cell receptors. Eur. J. Immunol. 1998, 28, 4391-4397.
9. Morita, M.; Natori, T.; Akimoto, K.; Osawa, T.; Fukusima, H.; Koezuka, Y. Syntheses of α-, β-monoglycosylceramides and four diastereomers of an α-galactosylceramide. Bioorg. Med. Chem. Lett. 1995, 5, 699-704.
10. Kobayashi, E.; Motoki, K.; Yamaguchi, Y.; Uchida, T.; Fukushima, H.; Koezuka, Y. Enhancing effects of α-, β-monoglycosylceramide on natural killer cell activity. Bioorg. Med. Chem. 1996, 4, 615-619.
11. Yamaguchi, Y.; Ueno, H.; Maeda, K.; Motoki, K.; Kobayashi, E.; Inoue, H.; Fukushima, H.; Koezuka, Y. Enhancing effects of (2S,3S,4R)-1-O-(α-D-galactopyranosyl)-2-N-hexacosanoylamino)-1,3,4- octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. 1996, 8, 399-407.
12. Iijima, H.; Kimura, K.; Sakai, T.; Uchimura, A.; Shimizu, T.; Ueno, H.; Natori, T.; Koezuka, Y. Structure-activity relationship and conformational analysis of monoglycosylceramides on the syngeneic mixed leukocyte reaction. Bioorg. Med. Chem. 1998, 6, 1905-1910.
13. Brossay, L.; Naidenko, O.; Burdin, N.; Matsuda, J.; Sakai, T.; Kronenberg, M. Strucural requirement for galactosylceramide recognized by CD1 restricted NKT cells. J. Immunol. 1998, 161, 5124-5128.
14. Wang, C.-R.; Castano, A. R.; Peterson, P. A.; Slaughter, C.; Fischer Lindahl, K.; Deisenhofer, J. Nonclassical binding of formulated peptide in crystal structure of the MHC class Ib molecule H2-M3. Cell 1995, 82, 655-664.
15. Zeng, Z. H.; Castano, A. R.; Segelke, B.; Stura, E. A.; Peterson, P. A.; Wilson, I. A. The crystal structure of mouse CD1: an MHC-like fold with a large hydrophobic binding groove. Science 1997, 277, 339-345.
16. Calabi, F.; Bradbury, A. The CD1 system. Tissue Antigens 1991, 37, 1-9.
17. Porcelli, S. A. The CD1 family: a third lineage of antigen-presenting molecules. Adv. Immunol. 1995, 59, 1-98.
18. + T cells. Nature 1994, 372, 691-694.
19. Ernst, W. A.; Maher, J.; Cho, S.; Niazi, K. R.; Chatterjee, D.; Moody, D. B.; Bersa, G. S.; Watanabe, Y.; Jensen, P. E.; Porcelli, S. A.; Kronenberg, M.; Modlin, R. Molecular interaction of CD1b with lipoglycan antigens. Immunity 1998, 8, 331-340.
20. Sugita, M.; Jackman, R. M.; Van Donselaar, E.; Behear, S. M.; Rogers, R. A.; Peters, P. J.; Brenner, M. B.; Porcelli, S. A. Cytoplasmic tail-dependent localization of CD1b antigen-presenting molecules to MIICs. Science 1996, 273, 349-352.
21. Prigozy, T. I.; Sieling, P. A.; Clemens, D.; Stewart, P. L.; Behar, S. M.; Porcelli, S. A.; Brenner, M. B.; Modlin, R. L.; Kronenberg, M. The mannose receptor delivers lipoglycan antigens to endosomes for presentation to T cells by CD1b molecules. Immunity 1997, 6, 187-197.
22. Jackman, R. M.; Stenger, S.; Lee, A.; Moody, D. B.; Rogers, R. A.; Niazi, K. R.; Sugita, M.; Modlin, R. L.; Peters, P. J.; Porcelli, S. A. The tyrosine-containing cytoplasmic tail of CD1b is essential for its efficient presentation of bacterial lipid antigens. Immunity, 1998, 8, 341-351.
23. + targets. J. Immunol. 1998, 160, 3681-3688.
24. Chui, Y.-H.; Jayawardena, J.; Weiss, A.; Lee, D.; Park, S.-H.; Dautry-Varsat, A.; Bendelac, A. Distinct subsets of CD1d-restricted T cells recognize self-antigens loaded in different cellular compartments. J. Exp. Med. 1999, 189, 103-110.
25. Castano, A. R.; Tangri, S.; Miller, J. E. W.; Holcombe, H. R.; Jackson, M. R.; Huse, W. D.; Kronenberg, M.; Peterson, P. A. Peptide binding and presenting properties of mouse CD1. Science 1995, 269, 223-226.